Association between pioglitazone and urothelial bladder cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Urology

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urology.2012.03.032PMID 22626574
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pioglitazone and Bladder Cancer

  2012cited by this paper
• Pioglitazone

  2012cited by this paper
• Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

  2011cited by this paper
• Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone

  2011cited by this paper
• Pioglitazone and bladder cancer.

  2011cited by this paper
• Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes

  2011cited by this paper
• Pioglitazone and bladder cancer – Authors' reply

  2011cited by this paper
• Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.

  2010cited by this paper
• Effects of PPAR agonists on proliferation and differentiation in human urothelium.

  2008cited by this paper
• Effects of PPARgamma and combined agonists on the urinary tract of rats and other species.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Effects of PPARγ and Combined Agonists on the Urinary Tract of Rats and Other Species

  2005cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Role of PPAR γ and EGFR signalling in the urothelial terminal differentiation programme

  2004cited by this paper
• Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)

  2001cited by this paper

• Pioglitazone Suppresses Urothelial Tumorigenesis In Vitro: A Potential Chemopreventive Agent

  2025cites this paper
• What is the prognosis of emphysematous pyelonephritis associated with extended-spectrum beta-lactamases producing microorganisms?

  2021cites this paper
• The impact of thiazolidinediones on the risk for prostate cancer in patients with type 2 diabetes mellitus: A review and meta-analysis

  2021cites this paper
• A selective modulator of peroxisome proliferator-activated receptor γ with unprecedented binding mode.

  2020cites this paper
• Safety and efficacy of retrograde intrarenal surgery for the treatment of renal stone in solitary kidney patients

  2018cites this paper
• Can hydrophilic coated catheters be beneficial for the public healthcare system in Brazil? - A cost-effectiveness analysis in patients with spinal cord injuries

  2018cites this paper
• Bladder Cancer and Other Urothelial Sites

  2018cites this paper
• Neuroprotective and immunomodulatory properties of the new PPARγ agonist MDG548: an in vitro and in vivo study in PD models

  2016cites this paper
• Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease

  2015cites this paper
• Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.

  2015cites this paper
• Effective radiation exposure evaluation during a one year follow-up of urolithiasis patients after extracorporeal shock wave lithotripsy

  2015cites this paper
• Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six‐year population‐based cohort study

  2014cites this paper
• A Review on Thiazolidinediones and Bladder Cancer in Human Studies

  2014cites this paper
• Will PPAR ‑g agonist therapy still have a role in diabetes management in 2013? MANAGEMENT PERSPECTIVE

  2013cites this paper
• Pioglitazone and cancer: angel or demon?

  2013cites this paper
• Rosiglitazone shows partial oncostatic effect in rat mammary carcinogenesis.

  2013cites this paper
• Will PPAR-γ agonist therapy still have a role in diabetes management in 2013?

  2013cites this paper